

**AMENDMENT TRANSMITTAL LETTER**Docket No.
WIBL-P01-548Application No.
10/085,982Filing Date
October 24, 2001Examiner
C. L. SmithArt Unit
1631Applicant(s): Hachon *et al.*

Invention: RESPONSE OF DENDRITIC CELLS TO A DIVERSE SET OF PATHOGENS

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	6	- 20 =		X	0.00
Independent Claims	6	- 14 =		X	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify): RCE fee					770.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					770.00

☒ Large Entity☐ Small Entity☐ No additional fee is required for this amendment.☒ Please charge Deposit Account No. 18-1945 in the amount of \$ 770.00.
A duplicate copy of this sheet is enclosed.☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.☐ Payment by credit card. Form PTO-2038 is attached.☒ The Director is hereby authorized to charge and credit Deposit Account No. 18-1945
as described below. A duplicate copy of this sheet is enclosed.☒ Credit any overpayment.☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.
Gloria Fuentes

Attorney Reg. No.: 47,580

Dated: August 11, 2004

ROPES & GRAY LLP
45 Rockefeller Plaza
New York, New York 10111-0087
(212) 497-3624

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ED181234831US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 11, 2004

Signature: 

(Andrea Silverman)

08-12-04

JFW RCE
1631

PTO/SB/30 (09-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Request For Continued Examination (RCE) Transmittal Address to: MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Application Number	10/085,982
	Filing Date	October 24, 2001
	First Named Inventor	Nir Hacohen <i>et al.</i>
	Art Unit	1631
	Examiner Name	C. L. Smith
	Attorney Docket Number	WIBL-P01-548

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).
- a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
- i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- ii. ☐ Other _____
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- iii. ☐ Information Disclosure Statement (IDS)
- ii. ☐ Affidavit(s)/Declaration(s)
- iv. ☐ Other _____
2. **Miscellaneous**
- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other _____
3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 18-1945
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other _____
- b. ☐ Check in the amount of \$ _____ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Gloria Fuentes	Registration No. (Attorney/Agent)	47,580
Signature			Date August 11, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ED181234831US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 11, 2004

(Andrea Silverman)

9511472.1

10085982

08/13/2004 MAIL11 00000078 181945

770.00 DA

01 FC:1801

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ED181234831US in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 11, 2004

Signature:

Andrea Silverman
(Andrea Silverman)

Docket No.: WIBL-P01-548
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hacohen *et al.*

Application No.: 10/085,982

Filed: October 24, 2001

For: RESPONSE OF DENDRITIC CELLS TO A
DIVERSE SET OF PATHOGENS

Confirmation No. 7046

Art Unit: 1631

Examiner: C. L. Smith

August 11, 2004

**AMENDMENT TO ACCOMPANY
REQUEST FOR CONTINUED EXAMINATION**

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

This Amendment is filed to accompany the Request for Continued Examination (RCE) being concurrently filed, and is in response to the final Office Action mailed May 11, 2004. The deadline for responding to the final Office Action mailed May 11, 2004 is August 11, 2004. Accordingly, this Amendment and accompanying RCE is being timely filed.

Please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.